Study on the Staging and Prognosis Model of Bladder Cancer
- Conditions
- Bladder Cancer
- Registration Number
- NCT06565923
- Brief Summary
Firstly, we retrospectively gathered the patient information who compliant with the criteria from 2012 to 2023, encompassing basic information, clinical information, along with MRI images, blood/urine samples, and tissue samples, for conducting relevant analyses of radiomics. Subsequently, based on artificial intelligence technology, deep learning and machine learning models were established on the basis of MRI radiomics and pathological histomics. Ultimately, the following research aims were accomplished: 1. Primary research objective: To explore the role of artificial intelligence and multimodal omics features in the staging and prognosis monitoring of bladder cancer. 2. Secondary objective: To explore the correlations among radiomics, case histomics, and test omics.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 200
-
- Patients with bladder cancer in preoperative examination; 2. Gender is not limited; 3. Age≥ 18 years old; 4. Be able to provide MRI images, pathological data and laboratory examination data before the operation; 5. Agree to provide basic personal clinical information and pathological and imaging data for scientific research use, and sign the informed consent form; 6. Agree to provide monitoring results during follow-up recurrence monitoring;
-
- Incomplete clinicopathological data; 2. Combined with upper tract urothelial carcinoma or previously diagnosed upper tract urothelial carcinoma; 3. Is participating in the rest of the clinical studies; Unable to cooperate with the relevant examinations of this project, and do not agree to sign the informed consent form.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) 2013- Progression-free survival (PFS) refers to the time from surgery until disease progression, the date of the last follow-up, or death from causes other than disease recurrence
Recurrence-Free Survival (RFS) 2013- Recurrence-Free Survival (RFS)
Overall survival (OS) 2013- Overall survival (OS) is defined as the duration from surgery to death or the date of the last follow-up.
- Secondary Outcome Measures
Name Time Method Tumor Infiltration Status 2013- Tumor Infiltration Status
Lymph node metastasis status 2013- Lymph node metastasis status
Trial Locations
- Locations (1)
The First Affiliated Hospital with Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China